Literature DB >> 26309184

Screening Magnetic Resonance Imaging-Based Prediction Model for Assessing Immediate Therapeutic Response to Magnetic Resonance Imaging-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids.

Young-sun Kim1, Hyo Keun Lim, Min Jung Park, Hyunchul Rhim, Sin-Ho Jung, Insuk Sohn, Tae-Joong Kim, Bilgin Keserci.   

Abstract

OBJECTIVES: The aim of this study was to fit and validate screening magnetic resonance imaging (MRI)-based prediction models for assessing immediate therapeutic responses of uterine fibroids to MRI-guided high-intensity focused ultrasound (MR-HIFU) ablation.
MATERIALS AND METHODS: Informed consent from all subjects was obtained for our institutional review board-approved study. A total of 240 symptomatic uterine fibroids (mean diameter, 6.9 cm) in 152 women (mean age, 43.3 years) treated with MR-HIFU ablation were retrospectively analyzed (160 fibroids for training, 80 fibroids for validation). Screening MRI parameters (subcutaneous fat thickness [mm], x1; relative peak enhancement [%] in semiquantitative perfusion MRI, x2; T2 signal intensity ratio of fibroid to skeletal muscle, x3) were used to fit prediction models with regard to ablation efficiency (nonperfused volume/treatment cell volume, y1) and ablation quality (grade 1-5, poor to excellent, y2), respectively, using the generalized estimating equation method. Cutoff values for achievement of treatment intent (efficiency >1.0; quality grade 4/5) were determined based on receiver operating characteristic curve analysis. Prediction performances were validated by calculating positive and negative predictive values.
RESULTS: Generalized estimating equation analyses yielded models of y1 = 2.2637 - 0.0415x1 - 0.0011x2 - 0.0772x3 and y2 = 6.8148 - 0.1070x1 - 0.0050x2 - 0.2163x3. Cutoff values were 1.312 for ablation efficiency (area under the curve, 0.7236; sensitivity, 0.6882; specificity, 0.6866) and 4.019 for ablation quality (0.8794; 0.7156; 0.9020). Positive and negative predictive values were 0.917 and 0.500 for ablation efficiency and 0.978 and 0.600 for ablation quality, respectively.
CONCLUSIONS: Screening MRI-based prediction models for assessing immediate therapeutic responses of uterine fibroids to MR-HIFU ablation were fitted and validated, which may reduce the risk of unsuccessful treatment.

Entities:  

Mesh:

Year:  2016        PMID: 26309184     DOI: 10.1097/RLI.0000000000000199

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  5 in total

1.  Thermal ablation of thyroid nodules: are radiofrequency ablation, microwave ablation and high intensity focused ultrasound equally safe and effective methods?

Authors:  Yücel Korkusuz; Daniel Gröner; Natascha Raczynski; Oleg Relin; Yasmina Kingeter; Frank Grünwald; Christian Happel
Journal:  Eur Radiol       Date:  2017-09-11       Impact factor: 5.315

2.  A risk assessment model for chronic ankle instability: indications for early surgical treatment? An observational prospective cohort - study protocol.

Authors:  Gwendolyn Vuurberg; Lauren M Wink; Leendert Blankevoort; Daniel Haverkamp; Robert Hemke; Sjoerd Jens; Inger N Sierevelt; Mario Maas; Gino M M J Kerkhoffs
Journal:  BMC Musculoskelet Disord       Date:  2018-07-18       Impact factor: 2.362

3.  Ultrasound-guided high-intensity focused ultrasound in the treatment of uterine fibroids.

Authors:  Hong-Jie Fan; Chao Zhang; Hong-Tao Lei; Jiang-Ping Cun; Wei Zhao; Jian-Qiang Huang; Yue Zhai
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

4.  Magnetic resonance-guided high-intensity focused ultrasound of uterine fibroids: whole-tumor quantitative perfusion for prediction of immediate ablation response.

Authors:  Chenxia Li; Chao Jin; Ting Liang; Xiang Li; Rong Wang; Yuelang Zhang; Jian Yang
Journal:  Acta Radiol       Date:  2019-11-28       Impact factor: 1.990

Review 5.  Uterine fibroid management: from the present to the future.

Authors:  Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Hum Reprod Update       Date:  2016-07-27       Impact factor: 15.610

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.